RESEARCH 研究の報告

2024.9.3

Prognostic significance of LAT1 expression in pleural mesothelioma.

著者 Taguchi R, Kaira K, Miura Y, Umesaki T, Mouri A, Imai H, Kagamu H, Yasuda M, Kanai Y, Nitanda H, Ishida H, Sakaguchi H.

Heliyon. 2024 Sep 3;10(17):e37414. doi: 10.1016/j.heliyon.2024.e37414. eCollection 2024 Sep 15.

PMID: 39290273 Free PMC article.

2024.9.1

A retrospective evaluation of therapeutic efficacy and safety of chemoradiotherapy in older patients (aged ≥ 75 years) with limited-disease small cell lung cancer: insights from two institutions and review of the literature.

著者 Shiono A, Imai H, Endo S, Katayama K, Sato H, Hashimoto K, Miura Y, Okazaki S, Abe T, Mouri A, Kaira K, Masubuchi K, Kobayashi K, Minato K, Kato S, Kagamu H.

Radiol Oncol. 2024 Sep 15;58(3):432-443. doi: 10.2478/raon-2024-0054. eCollection 2024 Sep 1.

PMID: 39287161 Free PMC article. Review.

2024.8.5

The Glasgow Prognostic Score as a Predictor of Survival after Chemoradiotherapy for Limited-Disease Small Cell Lung Cancer.

著者 Endo S, Imai H, Shiono A, Hashimoto K, Miura Y, Okazaki S, Abe T, Mouri A, Kaira K, Masubuchi K, Masubuchi T, Kobayashi K, Minato K, Kato S, Kagamu H.

Oncology. 2024 Aug 5:1-11. doi: 10.1159/000540651. Online ahead of print.

PMID: 39102792

2024.7.1

Clinical Issue of Myasthenia Gravis Related to Immune Checkpoint Inhibitors.

著者 Kaira K, Mouri A, Imai H, Yamaguchi O, Kagamu H.

Curr Oncol Rep. 2024 Sep;26(9):1113-1119. doi: 10.1007/s11912-024-01571-0. Epub 2024 Jul 1.

PMID: 38954314 Review.